The Administrative Core will provide management services to each of the Projects and Cores in thisProgram. The Core will provide financial, adminstrative, and clerical services for the PI, the Co-Pi, ProjectLeaders, and Core Leaders for all grant-related activities. These activites include the preparation of thiscompeting renewal, non-competing renewals including progress reports, preparation of budgets,communication with the NIH regarding renewals and all financial interactions, and assurance that the labssupported by this Program are in full compliance with all institutional, state and federal regulations. Core Awill also coordinate and scheduling all meetings related to the function of the Program, including monthlymeetings of all Project and Core Leaders, and members of their respective laboratories, as well as twiceyearly meetings of the Internal and External Advisory Boards. Core A will also coordinate efforts with off-siteinvestiators at the three neighboring institutions, Brigham and Women's Hospital, Beth Israel-DeaconessHospital, and Children's Hospital of Boston, as well as interaction with the investigators at the DFCI. Dr.Gilliland is the PI and Director of this Core, and will serve as the overall scientific director and chiefadministrator. Dr. Griffin is the Co-Pi and will assist in these operations, particaulrly with regard to matterswith the on-site investigators and clinical programs at the DFCI. He will assist Dr. Gilliland in monitoringprotocol performance and will assist in protocol development. Alberto Jamarillo is a highly skilledadministrator with experience in management of fiscal and administrative matters for large program projectgrants. He will serve as Administrative Facilitator, and coordinate Program administration and fiscaloversight with Dr. Gilliland and Dr. Griffin. Alberto Jamarillo will be assisted by Betsy Kelley, a GrantsManagement Specialist/Post Award, and Mariha Duarte, an administrative assistant, in coordination with Dr.Gilliland and Dr. Griffin, to manage budgets between participating institutions, prepare reports including noncompetingrenewals, interface with the financial officers of each participating institution in the Program, andserve as an interface between these groups and the NIH. In addition, the Administrative Core will assurecompliance with appropriate regulations regarding experimentation with human subjects, (including genderand minority participation) and vertebrate animals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA066996-11A1
Application #
7406278
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (O1))
Project Start
2007-12-01
Project End
2012-11-30
Budget Start
2007-12-01
Budget End
2009-03-31
Support Year
11
Fiscal Year
2008
Total Cost
$43,199
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
List, Alan; Ebert, Benjamin L; Fenaux, Pierre (2018) A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. Leukemia 32:1493-1499
Ebert, Benjamin L; Krönke, Jan (2018) Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia. N Engl J Med 379:1873-1874
Sellar, Rob S; Jaiswal, Siddhartha; Ebert, Benjamin L (2018) Predicting progression to AML. Nat Med 24:904-906
Hshieh, Tammy T; Jung, Wooram F; Grande, Laura J et al. (2018) Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. JAMA Oncol 4:686-693
Patel, Sanjay S; Kuo, Frank C; Gibson, Christopher J et al. (2018) High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood 131:2816-2825
Montero, Joan; Letai, Antony (2018) Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ 25:56-64
DeAngelo, Daniel J; Brunner, Andrew M; Werner, Lillian et al. (2018) A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol 93:254-261
Fink, Emma C; McConkey, Marie; Adams, Dylan N et al. (2018) CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood 132:1535-1544
Wroblewski, Mark; Scheller-Wendorff, Marina; Udonta, Florian et al. (2018) BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. Haematologica 103:939-948
Konopleva, Marina; Letai, Anthony (2018) BCL-2 inhibition in AML: an unexpected bonus? Blood 132:1007-1012

Showing the most recent 10 out of 376 publications